Earnings Healthy, Genzyme’s Bigger-Batch Myozome Plant On Track For Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
2,000-liter version of Pompe therapy, rebranded as Lumizyme, due for action later this month.
You may also be interested in...
Drug Safety Problems Show Potential For Follow-On Biologics, Jaeger Says
GPhA President Jaeger argues that improved analytics developed in the wake of the heparin problems suggest that non-clinical verification of follow-on products is possible.
Drug Safety Problems Show Potential For Follow-On Biologics, Jaeger Says
GPhA President Jaeger argues that improved analytics developed in the wake of the heparin problems suggest that non-clinical verification of follow-on products is possible.
FDA Agrees To Accelerated Approval For Myozyme Scale-Up, Genzyme Says
The 2,000L version of Myozyme on track for approval with a post-market confirmatory trial in February; user fee date extended while FDA reviews REMS submission.